The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4 -induced contractions in passively sensitized human airways-Reference-Cited by-同舟云学术

The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4 -induced contractions in passively sensitized human airways

Published:2000-12 Issue:8 Volume:131 Page:1607-1618
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

Schmidt Dunja T,Watson Nikki,Dent Gordon,Rühlmann Elke,Branscheid Detlev,Magnussen Helgo,Rabe Klaus F

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/sj.bjp.0703725/fullpdf

Reference52 articles.

1. Effect of isoenzyme-selective inhibitors of phosphodiesterase (PDE) on human lung mast cells (HLMC);ANDERSON;FASEB J.,1994

2. Selective type IV phosphodiesterase inhibitors as anti-asthmatic agents: the synthesis and biological activities of 3-cyclopentyloxy-4-methoxybenzamides and analogues;ASHTON;J. Med. Chem.,1994

3. Anti-inflammatory effects of theophylline and selective phosphodiesterase inhibitors;BANNER;Clin. Exp. Allergy,1996

4. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms;BEAVO;Physiol. Rev.,1995

5. Phosphodiesterase inhibition and theophylline;BERGSTRAND;Eur. J. Respir. Dis.,1980

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What role will ensifentrine play in the future treatment of chronic obstructive pulmonary disease patients? Implications from recent clinical trials;Immunotherapy;2023-12

2. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials);American Journal of Respiratory and Critical Care Medicine;2023-08-15

3. Synergy across the drugs approved for the treatment of asthma;Minerva Medica;2022-03

4. Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease;US Respiratory & Pulmonary Diseases;2022

5. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease;Drugs;2021-11